

**MARYLAND INSURANCE ADMINISTRATION  
SEPTEMBER 25, 2017  
PHARMACEUTICAL SERVICES WORKGROUP  
MEETING 3 AGENDA**

**I. Opening Remarks – Refining our search for common ground?**

**II. Next Meeting (#4)**

**Tuesday, October 23, 2017**

**1 to 4PM**

MIA Hearing Room, 24th Floor

200 St. Paul Place

Baltimore, MD 21202

**III. Specialty Drugs**

- 1) Should the definition of Specialty Drug be amended, specifically at § 15-847(a)(5)(ii) to recognize a higher cost than \$600 for a 30 day supply?
  - a. Is \$1,000 high enough to make an impact?
  - b. Is \$2,500 too high?
  - c. What are the impacts, if any, on premiums if the \$600 amount is raised?
  
- 2) What accreditation organizations other than URAC are there for specialty pharmacy?
  - a. Joint Commission Accreditation , Accreditation Commission for Health Care, Community Health Accreditation Program, Center for Pharmacy Practice Accreditation (CPPA)
  - b. Which if any of these other accreditations are potentially acceptable to Carriers, Plans, and Pharmacy Benefit Managers?
  - c. What are the negatives or perceived issues with the other accreditations?

**IV. Wrap Up**